Use of vancomycin pharmacokinetic–pharmacodynamic properties in the treatment of MRSA infections

References

• Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin. Infect. Dis.44(9), 1208–1215 (2007).
   PubMed Web of Science ®Google Scholar
• Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis.46(2), 193–200 (2008).
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol.42(6), 2398–2402 (2004).
   PubMed Web of Science ®Google Scholar
• Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med.166(19), 2138–2144 (2006).
   PubMed Web of Science ®Google Scholar
• Lodise TP, Miller CD, Graves J et al. Predictors of high vancomycin MIC values among patients with methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother.62(5), 1138–1141 (2008).
   PubMed Web of Science ®Google Scholar
• Lodise TP, Graves J, Evans A et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother.52(9), 3315–3320 (2008).
   PubMed Web of Science ®Google Scholar
• Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am. J. Respir. Crit. Care Med.171, 388–416 (2005).
   PubMed Web of Science ®Google Scholar
• Baddour LM, Wilson WR, Bayer AS et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation111(23), e394–e434 (2005).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis.41(10), 1373–1406 (2005).
   PubMed Web of Science ®Google Scholar
• Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health Syst. Pharm.66(1), 82–98 (2009).
   PubMedGoogle Scholar
• Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of b-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am.17(3), 479–501 (2003).
   PubMed Web of Science ®Google Scholar
• Knudsen JD, Fuursted K, Raber S, Espersen F, Frimodt-Moller N. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection. Antimicrob. Agents Chemother.44(5), 1247–1254 (2000).
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet.43(13), 925–942 (2004).
   PubMed Web of Science ®Google Scholar
• Jeffres MN, Isakow W, Doherty JA et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest130(4), 947–955 (2006).
   PubMed Web of Science ®Google Scholar
• Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis.44(5), 1536–1542 (2007).
   PubMed Web of Science ®Google Scholar
• Rose WE, Leonard SN, Rossi KL, Kaatz GW, Rybak MJ. Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother.53(2), 805–807 (2009).
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Gold HS, Cohen RA et al. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J. Antimicrob. Chemother.57(4), 699–704 (2006).
   PubMed Web of Science ®Google Scholar
• Sakoulas G, Eliopoulos GM, Moellering RC Jr et al.Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J. Infect. Dis.187(6), 929–938 (2003).
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Rybak MJ, Lau KL, Sakoulas G. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother.51(3), 1089–1091 (2007).
   PubMed Web of Science ®Google Scholar
• Healy DP, Sahai JV, Fuller SH, Polk RE. Vancomycin-induced histamine release and ‘red man syndrome’: comparison of 1- and 2-hour infusions. Antimicrob. Agents Chemother.34(4), 550–554 (1990).
   PubMed Web of Science ®Google Scholar
• Pai MP, Mercier RC, Koster SA. Epidemiology of vancomycin-induced neutropenia in patients receiving home intravenous infusion therapy. Ann. Pharmacother.40(2), 224–228 (2006).
   PubMedGoogle Scholar
• Von Drygalski A, Curtis BR, Bougie DW et al. Vancomycin-induced immune thrombocytopenia. N. Engl. J. Med.356(9), 904–910 (2007).
   PubMed Web of Science ®Google Scholar
• Forouzesh A, Moise PA, Sakoulas G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob. Agents Chemother.53(2), 483–486 (2009).
   PubMed Web of Science ®Google Scholar
• Bailie GR, Neal D. Vancomycin ototoxicity and nephrotoxicity. A review. Med. Toxicol. Adverse Drug Exp.3(5), 376–386 (1988).
   PubMedGoogle Scholar
• Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration–time profile and nephrotoxicity among hospitalized patients. Clin. Infect. Dis.49(4), 507–514 (2009).
   PubMed Web of Science ®Google Scholar
• Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin. Ther.29(6), 1107–1115 (2007).
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J. Antimicrob. Chemother.25(4), 679–687 (1990).
   PubMed Web of Science ®Google Scholar
• Lodise TP, Lomaestro B, Graves J, Drusano GL. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob. Agents Chemother.52(4), 1330–1336 (2008).
   PubMed Web of Science ®Google Scholar
• Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001–05. J. Antimicrob. Chemother.60(4), 788–794 (2007).
   PubMed Web of Science ®Google Scholar
• Clinical Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: Eighteenth Informational Supplement. Volume 27–28, January (2008).
   Google Scholar
• Prakash V, Lewis JS 2nd, Jorgensen JH. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob. Agents Chemother.52(12), 4528 (2008).
   PubMed Web of Science ®Google Scholar
• Sader HS, Rhomberg PR, Jones RN. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother.53(7), 3162–3165 (2009).
   PubMed Web of Science ®Google Scholar
• Hsu DI, Hidayat LK, Quist R et al. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents32(5), 378–385 (2008).
   PubMed Web of Science ®Google Scholar
• Cruciani M, Gatti G, Lazzarini L et al. Penetration of vancomycin into human lung tissue. J. Antimicrob. Chemother.38(5), 865–869 (1996).
   PubMed Web of Science ®Google Scholar
• Georges H, Leroy O, Alfandari S et al. Pulmonary disposition of vancomycin in critically ill patients. Eur. J. Clin. Microbiol. Infect. Dis.16(5), 385–388 (1997).
   PubMed Web of Science ®Google Scholar
• Lamer C, de Beco V, Soler P et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob. Agents Chemother.37(2), 281–286 (1993).
   PubMed Web of Science ®Google Scholar
• Viladrich PF, Gudiol F, Linares J et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob. Agents Chemother.35(12), 2467–2472 (1991).
   PubMed Web of Science ®Google Scholar
• Ricard JD, Wolff M, Lacherade JC et al. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin. Infect. Dis.44(2), 250–255 (2007).
   PubMed Web of Science ®Google Scholar
• Daschner FD, Frank U, Kummel A et al. Pharmacokinetics of vancomycin in serum and tissue of patients undergoing open-heart surgery. J. Antimicrob. Chemother.19(3), 359–362 (1987).
   PubMed Web of Science ®Google Scholar
• Graziani AL, Lawson LA, Gibson GA, Steinberg MA, MacGregor RR. Vancomycin concentrations in infected and noninfected human bone. Antimicrob. Agents Chemother.32(9), 1320–1322 (1988).
   PubMed Web of Science ®Google Scholar
• Skhirtladze K, Hutschala D, Fleck T et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob. Agents Chemother.50(4), 1372–1375 (2006).
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Albrecht LM, Berman JR, Warbasse LH, Svensson CK. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob. Agents Chemother.34(5), 792–795 (1990).
   PubMed Web of Science ®Google Scholar
• Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob. Agents Chemother.21(4), 575–580 (1982).
   PubMed Web of Science ®Google Scholar
• Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur. J. Clin. Pharmacol.54(8), 621–625 (1998).
   PubMed Web of Science ®Google Scholar
• Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther. Drug Monit.16(5), 513–518 (1994).
   PubMed Web of Science ®Google Scholar
• Llopis-Salvia P, Jimenez-Torres NV. Population pharmacokinetic parameters of vancomycin in critically ill patients. J. Clin. Pharm. Ther.31(5), 447–454 (2006).
   PubMedGoogle Scholar
• del Mar Fernandez de Gatta Garcia M, Revilla N, Calvo MV, Dominguez-Gil A, Sanchez Navarro A. Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients. Intensive Care Med.33(2), 279–285 (2007).
   PubMed Web of Science ®Google Scholar
• Dailly E, Le Floch R, Deslandes G, Pannier M, Jolliet P. Influence of glomerular filtration rate on the clearance of vancomycin administered by continuous infusion in burn patients. Int. J. Antimicrob. Agents31(6), 537–539 (2008).
   PubMedGoogle Scholar
• Scheetz MH, Wunderink RG, Postelnick MJ, Noskin GA. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy26(4), 539–550 (2006).
   PubMed Web of Science ®Google Scholar
• Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ. Antibiotic tissue penetration and its relevance: models of tissue penetration and their meaning. Antimicrob. Agents Chemother.35(10), 1947–1952 (1991).
   PubMed Web of Science ®Google Scholar
• Arda B, Yamazhan T, Sipahi OR et al. Meningitis due to methicillin-resistant Staphylococcus aureus (MRSA): review of 10 cases. Int. J. Antimicrob. Agents25(5), 414–418 (2005).
   PubMed Web of Science ®Google Scholar
• Albanese J, Leone M, Bruguerolle B et al. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob. Agents Chemother.44(5), 1356–1358 (2000).
   PubMed Web of Science ®Google Scholar
• Fernandez Guerrero ML, Gonzalez Lopez JJ, Goyenechea A, Fraile J, de Gorgolas M. Endocarditis caused by Staphylococcus aureus : a reappraisal of the epidemiologic, clinical, and pathologic manifestations with analysis of factors determining outcome. Medicine (Baltimore)88(1), 1–22 (2009).
   PubMed Web of Science ®Google Scholar
• Nakayama H, Echizen H, Tanaka M, Sato M, Orii T. Reduced vancomycin clearance despite unchanged creatinine clearance in patients treated with vancomycin for longer than 4 weeks. Ther. Drug Monit.30(1), 103–107 (2008).
   PubMedGoogle Scholar
• Bone and joint infections. In: Pharmacotherapy, A Pathophysiologic Approach (7th Edition). DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (Eds). Appleton & Lange, CT, USA (2008).
   Google Scholar
• Vancomycin, package insert. Baxter Healthcare Corporation, IL, USA (2008).
   Google Scholar
• Hall RG 2nd, Payne KD, Bain AM et al. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am. J. Med.121(6), 515–518 (2008).
   PubMed Web of Science ®Google Scholar
• Vance-Bryan K, Guay DR, Gilliland SS, Rodvold KA, Rotschafer JC. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob. Agents Chemother.37(3), 436–440 (1993).
   PubMed Web of Science ®Google Scholar
• Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med.130(24), 461–470 (1999).
   PubMed Web of Science ®Google Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron16(1), 31–41 (1976).
   PubMed Web of Science ®Google Scholar
• Matzke GR, Kovarik JM, Rybak MJ, Boike SC. Evaluation of the vancomycin-clearance:creatinine-clearance relationship for predicting vancomycin dosage. Clin. Pharm.4(3), 311–315 (1985).
   PubMedGoogle Scholar
• Murphy JE, Gillespie DE, Bateman CV. Predictability of vancomycin trough concentrations using seven approaches for estimating pharmacokinetic parameters. Am. J. Health Syst. Pharm.63(23), 2365–2370 (2006).
   PubMed Web of Science ®Google Scholar
• Wang JT, Fang CT, Chen YC, Chang SC. Necessity of a loading dose when using vancomycin in critically ill patients. J. Antimicrob. Chemother.47(2), 246 (2001).
   PubMed Web of Science ®Google Scholar
• Klepser ME, Patel KB, Nicolau DP, Quintiliani R, Nightingale CH. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. Pharmacotherapy18(5), 1069–1074 (1998).
   PubMed Web of Science ®Google Scholar
• James JK, Palmer SM, Levine DP, Rybak MJ. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented Gram-positive infections. Antimicrob. Agents Chemother.40(3), 696–700 (1996).
   PubMed Web of Science ®Google Scholar
• Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob. Agents Chemother.45(9), 2460–2467 (2001).
   PubMed Web of Science ®Google Scholar